Ensysce Biosciences
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
7946 Ivanhoe Ave Ste 201, La Jolla, Cali...Phone Number
(858) 263-4196Website
www.ensysce.comRevenue
<$5 MillionStock Symbol
ENSCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
1
1
1
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage biotechnology company focused on developing innovative oral drug delivery technologies designed to improve the safety of prescription medications, particularly in the treatment of severe and chronic pain. The companys proprietary platforms aim to reduce risks of drug abuse, misuse, and overdose by using advanced chemistry-based mechanisms that control how active drug ingredients are released and activated in the body. Its research and development efforts are centered on creating safer opioid and non-opioid therapies, supported by collaborations with research institutions and industry partners.Explore more
Ensysce Biosciences Org Chart
WS
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ensysce Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Ensysce Biosciences recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Ensysce Biosciences
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Ensysce Biosciences has new funding data
Check if Ensysce Biosciences has recently received funding, and reach out quickly before it becomes old news!
Check out if Ensysce Biosciences is spiking on competitors!
Product Launch: Get notified when Ensysce Biosciences launches new products
Click to see if Ensysce Biosciences had a recent Job posting/layoffs
Ensysce Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Ensysce Biosciences
Find more new buyers
Compare Similar Companies to Ensysce Biosciences
Compare insights from companies similar to Ensysce Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$11.5M
51-200
Private
-
1990
HS
Harpreet SmithVice President and General Manager, Quotient Sciences - Miami
Company Profile Activity
Activity Insights
Ensysce Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ensysce Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ensysce Biosciences.
Ensysce Biosciences financials insights
Gather financial insights about Ensysce Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$60M
2022
Debt
$8M
2026
Stock/Share Issuance
$2M
Ensysce Biosciences Tech Stack
A closer look at the technologies used by Ensysce Biosciences
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Earnings
Product Development, Business Development
Funding
New Hire
Executive Move
Ensysce Biosciences News & Media
Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript
Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call January 7, 2026 12:00 PM ESTCompany ParticipantsRobert GowerDavid Humphrey - CFO, Secretary &...Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)
New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The research summary below is from a report commissioned by Ensysce Biosciences, Inc. and produced by Diamond Equity Research. The update note includes information on Ensysce Biosciences’ business updates, management commentary, financial results, valuation, and risks.Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million ... - The Joplin Globe
~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~Ensysce Biosciences Secures $4M, Access to $20M for PF614 | ENSC Stock News
Ensysce closes $4M convertible preferred financing with up to $16M over 24 months, $2.50 conversion price and 50% warrant coverage for 5 years.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ensysce Biosciences
Sign Up For FreeTo access detailed company insights
Ensysce Biosciences is a clinical-stage biotechnology company focused on developing innovative oral drug delivery technologies designed to improve the safety of prescription medications, particularly in the treatment of severe and chronic pain. The companys proprietary platforms aim to reduce risks of drug abuse, misuse, and overdose by using advan... Read More
